Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02316197
Recruitment Status : Completed
First Posted : December 12, 2014
Last Update Posted : April 13, 2018
Information provided by (Responsible Party):
Merck KGaA, Darmstadt, Germany

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 29, 2017
Actual Study Completion Date : June 29, 2017